SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-044806
Filing Date
2024-04-16
Accepted
2024-04-16 16:30:23
Documents
17
Period of Report
2024-06-07

Document Format Files

Seq Description Document Type Size
1 PRE 14A akro-20240416.htm   iXBRL PRE 14A 1541723
2 GRAPHIC img235425615_0.jpg GRAPHIC 13695
3 GRAPHIC img235425615_1.jpg GRAPHIC 70754
4 GRAPHIC img235425615_2.jpg GRAPHIC 70894
5 GRAPHIC img235425615_3.jpg GRAPHIC 274295
6 GRAPHIC img235425615_4.jpg GRAPHIC 177621
  Complete submission text file 0000950170-24-044806.txt   3497536

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT akro-20240416.xsd EX-101.SCH 27091
20 EXTRACTED XBRL INSTANCE DOCUMENT akro-20240416_htm.xml XML 78278
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38944 | Film No.: 24848173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)